Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOKGet Rating) in a research note issued on Wednesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

Shares of EVOK opened at $1.50 on Wednesday. The firm has a market cap of $5.01 million, a price-to-earnings ratio of -0.55 and a beta of 0.67. The company’s fifty day moving average is $1.83 and its 200-day moving average is $2.55. The company has a quick ratio of 6.94, a current ratio of 7.06 and a debt-to-equity ratio of 0.90. Evoke Pharma has a 12 month low of $1.44 and a 12 month high of $16.80.

Evoke Pharma Company Profile

(Get Rating)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females.

Further Reading

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.